Company Description
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases.
Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases.
The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19.
It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease.
Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD.
The company was incorporated in 2006 and is headquartered in Paris, France.
| Country | France |
| Founded | 2006 |
| IPO Date | Feb 10, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Stanislas Veillet Ph.D. |
Contact Details
Address: Sorbonne University, Bc 9, Batiment A 4eme Etage, 4 Place Jussieu Paris, I0 75001 France | |
| Phone | 33 1 44 37 23 00 |
| Website | biophytis.com |
Stock Details
| Ticker Symbol | BPTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.75 |
| CIK Code | 0001768946 |
| CUSIP Number | 09076G104 |
| ISIN Number | US09076G2030 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stanislas Veillet Ph.D. | Chairman of the Board and Chief Executive Officer |
| Nicolas Fellmann | Chief Financial Officer |
| Waly Dioh Ph.D. | Chief Clinical Operating Officer |
| Dr. Pierre J. Dilda | Chief Scientific Officer |
| Dr. Rene Lafont | Scientific Advisor and Member of Scientific Advisory Board |
| Dr. Rob van Maanen FFPM, M.B.A., M.D. | Chief Medical Officer |
| Edouard Bieth | Chief Business Officer |
| _ Teylan | Financial Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 19, 2024 | 6-K | Report of foreign issuer |
| Apr 18, 2024 | 6-K | Report of foreign issuer |
| Apr 15, 2024 | 6-K | Report of foreign issuer |
| Apr 9, 2024 | 6-K | Report of foreign issuer |
| Apr 9, 2024 | 6-K | Report of foreign issuer |
| Apr 8, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 5, 2024 | 6-K | Report of foreign issuer |
| Mar 22, 2024 | 6-K | Report of foreign issuer |
| Mar 18, 2024 | 6-K | Report of foreign issuer |